This study investigates Claudin 18.2-positive pancreatic cancer. The purpose of this study is to evaluate the investigational medication compared to a placebo.
The study focuses on understanding the overall survival of participants. It evaluates the safety and effectiveness of the investigational medication.
- Who can participate: Adults with Claudin 18.2-positive pancreatic cancer who have had at least two prior treatments and have good bone marrow and organ function with an ECOG score of 0 or 2 can participate.
- Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.